Publications by authors named "Goda Juzenaite"

Article Synopsis
  • The FDA approved plerixafor as a hematopoietic stem cell (HSC) mobilizer, leading to the exploration of oral CXCR4 antagonists like AMD11070.
  • Although AMD11070 is a strong antagonist in lab tests, it is less effective in actual HSC mobilization compared to plerixafor.
  • Plerixafor not only blocks the receptor but also encourages a process that reduces receptor levels, enhancing its effectiveness in mobilizing HSCs in vivo.
View Article and Find Full Text PDF

The rapid response of neutrophils throughout the body to a systemic challenge is a critical first step in resolution of bacterial infection such as (). Here we delineated the dynamics of this response, revealing novel insights into the molecular mechanisms using lung and spleen intravital microscopy and 3D culture of living precision cut splenic slices in combination with fluorescent labelling of endogenous leukocytes. Within seconds after challenge, intravascular marginated neutrophils and lung endothelial cells (ECs) work cooperatively to capture pathogens.

View Article and Find Full Text PDF

Treatment with the CXCR4 antagonist, plerixafor (AMD3100), has been proposed for clinical use in patients with WHIM (warts, hypogammaglobulinemia, infections, and myelokathexis) syndrome and in pulmonary fibrosis. However, there is controversy with respect to the impact of plerixafor on neutrophil dynamics in the lung, which may affect its safety profile. In this study, we investigated the kinetics of endogenous neutrophils by direct imaging, using confocal intravital microscopy in mouse bone marrow, spleen, and lungs.

View Article and Find Full Text PDF